Jim Cramer's Stop Trading: GW Pharmaceuticals Is 'A Winner'

NEW YORK (TheStreet) -- Shares of GW Pharmaceuticals (GWPH) are trading higher following the pricing of the company's secondary stock offering. 

The company plans to sell 1.7 million shares at $86.83, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio

On CNBC's "Cramer's Stop Trading" segment, he said that many investors thought the secondary offering would put a halt to the recent rally.

However, this stock is "a winner," he reasoned, saying that most doctors who look to prescribe a cannabinoid treatment "have a hard time trusting any other brand" -- making GW Pharmaceuticals stand out.

"This will replace Oxycodone, that's my prediction," Cramer said in regards to pain management via cannabis-related treatments. 

GW Pharmaceuticals is "not a penny stock or a marijuana stock," he concluded, it's "a pain-killing company." 

-- Written by Bret Kenwell in Petoskey, Mich.

Adobe, FedEx Hit All-Time Highs on Strong Earnings

Sneakers at Work Are Running Up Sales for Nike, Foot Locker

Prestigious Cancer Hospital Rebukes Northwest Bio for 'Inappropriate' Data Disclosures

Home Short-Sellers Could Face a Huge Hidden Tax

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)